Secondary myelodysplastic syndrome in patients with multiple myeloma


如何引用文章

全文:

参考

  1. Bergsagel D. Е., Bailey A. I., Langley A. I. et al. The chemoherapy of plasma cell myeloma and the incidence of acute leukemia. N. Engl. J. Med. 1979; 301: 743-758.
  2. Bergsagel D. E. Plasma cell neoplasm and acute leukemia. Clin. Haematol. 1982; 11: 221-234.
  3. Cuzick I., Erskine S., Edelman D. et al. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukemia following melphalan and cyclophosphamide treatment for myelomatosis. Br. J. Cancer 1987; 55: 523-529.
  4. Schmetzer H. M., Mittermuller J., Duell T. et al. Development of myeloma and secondary myelodysplastic syndrome from a common clone. Cancer Genet. Cytogenet. 1998; 100: 31-35.
  5. Leone J., Mele L., Pulsoni A. et al. The incidence of secondary leukemias. Haematologica 1999; 84: 937-945.
  6. Chen N. J., Sandler D. P., Taylor J. A. et al. Increased risk for myelodysplastic syndromes in individuals with glutathion transferase theta 1 (GSTT1) gene defect. Lancet 1996; 347: 295297.
  7. Bennet J. M., Catovsky D., Daniel M. T. et al. Proposals for the classification of the myelodysplastic syndromes.Br. J. Haematol. 1982; 51: 189-199.
  8. Raza A., Quwi H., Andric T. et al. Pentoxifylline, cyprofloxacin and dexamethasone improve the ineffective hematopoiesis in myeloldysplastic syndrome patients. Hematol. 2000; 5: 275- 284.
  9. Raza A., Quwi H., Lisak L. et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and cyprofloxacin with or without dexamethasone. Blood 2000; 95: 1580-1587.
  10. Michels S. D., McKenna R. W., Arthur D. C., Bruhning R. D. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphological study of 65 cases. Blood 1985; 66: 1372-1385.
  11. Govindarajan R. A., Jagannath S., Flick J. T. et al. Preceding standard therapy is the likely cause of MDS after autotransplantats for multiple myeloma. Br. J. Haematol. 1996; 95: 349-353.
  12. Thirman M. J., Larson R. A. Therapy-related myeloid leukemia. Hematol. Oncol. Clin. N. Am. 1996; 10: 293-320.
  13. Lesesve J. F., Troussard X., Bastard С. et al. P190 bcr/abl rearrangement in myelodysplastic syndromes: two reports and review of the literature. Br. J. Hematol. 1996; 95: 172-175.
  14. Nakamura K., Inaba Т., Nishimura J. et al. Molecular analysis of BCR/ABL production in a case of myelodysplastic syndrome with late appearing Philadelphia chromosome. Br. J. Hematol. 1991; 78: 130-132.
  15. Bertolini F., Mingrone W., Alietti A. et al. Thalidomide in multiple myeloma, myeloldysplatic syndromes sand hystiocytosis. Analysis of clinical results and surrogate angiogenesis markers. Ann. Oncol. 2001; 12: 987-990.
  16. Raza A., Meyer P., Dutt D. et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958-965.
  17. Lubbert M., Wijermans P., Kanzmann R. et al. Cytogenetic responses in high-risk myelodysplastic syndromes following lowdose treatment with the DNA methylation inhibitor 5-aza-2'deoxycytidiine. Br. J. Haematol. 2001; 114: 349-357.
  18. Silverman L. R., Demakos E. P., Peterson B. L. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J. Clin. Oncol. 2002; 20: 2429-2440.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2004

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##